(Eplivanserin + volinanserin) is under clinical development by Terran Biosciences and currently in Phase III for Unspecified Psychiatric Disorders. According to GlobalData, Phase III drugs for Unspecified Psychiatric Disorders have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Eplivanserin + volinanserin)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Eplivanserin + volinanserin) overview
Fixed dose combination of eplivanserin and volinanserin is under development for the treatment of unspecified neuropsychiatric illnesses. It acts by targeting 5-hydroxytryptamine receptor 2A.
Terran Biosciences overview
Terran Biosciences is a biotech platform company that focuses on the discovery and development of next-generation therapeutics for neurological and psychiatric disorders. The company’s portfolio includes a late-stage therapy for schizophrenia, selective serotonin 2A receptor antagonists, a drug design engine for psychedelic therapies and an AI-enabled imaging software platform. It’s pipeline include Idazoxan XR, Eplivanserin, Volinanserin and a range of psychedelics and empathogens. Terran Biosciences is headquartered in New York City, New York, US.
For a complete picture of (Eplivanserin + volinanserin)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
